Lake Street Capital started coverage on shares of Anteris Technologies Global (NASDAQ:AVR – Free Report) in a research note published on Wednesday, MarketBeat.com reports. The firm issued a buy rating and a $20.00 price objective on the stock.
Other research analysts have also issued reports about the company. TD Cowen assumed coverage on Anteris Technologies Global in a research report on Tuesday. They set a “buy” rating and a $15.00 target price for the company. Barclays initiated coverage on Anteris Technologies Global in a research report on Tuesday. They set an “overweight” rating and a $22.00 price objective for the company. Finally, Cantor Fitzgerald began coverage on Anteris Technologies Global in a report on Tuesday. They issued an “overweight” rating and a $9.00 target price on the stock.
Read Our Latest Analysis on Anteris Technologies Global
Anteris Technologies Global Trading Down 2.1 %
Anteris Technologies Global Company Profile
Anteris Technologies Global Corp. engages in the development and commercialization of medical devices for heart diseases. The company was founded in 1999 and is headquartered in Eagan, MN.
Read More
- Five stocks we like better than Anteris Technologies Global
- Do ETFs Pay Dividends? What You Need to Know
- Breaking the Mold: 3 Non-Tech Stocks Ready to Surge in 2025
- Unveiling The Power Of VWAP: A Key Indicator For Traders
- Your Best Trading Year Starts Here: Top 3 Stocks for 2025 Gains
- Insider Buying Explained: What Investors Need to Know
- Warren Buffett Bets on the Digital Economy With New VeriSign Buy
Receive News & Ratings for Anteris Technologies Global Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anteris Technologies Global and related companies with MarketBeat.com's FREE daily email newsletter.
